SCHEMBL5035259

SCHEMBL5035259

COc1ccc(N(C(=O)c2ccc(Cl)cc2Cl)c2nc(C(=O)O)c(C)s2)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
TTR P02766 1/20 0.39
TSHR P16473 2/20 0.39
CYP3A4 P08684 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.36
MAPT P10636 4/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 2/20 0.35
POLB P06746 1/20 0.35
PYGL P06737 1/20 0.35
THRB P10828 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5032537 0.94 CYP3A4 (0.38) TTRTSHRCYP3A4MRGPRX4MAPT
SCHEMBL5032638 0.90 FLT1 (0.38) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5034805 0.88 CYP3A4 (0.42) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5035943 0.88 CYP3A4 (0.47) TSHRCYP3A4MAPTKMT2ARAB9A
SCHEMBL5035881 0.87 KMT2A (0.39) FLT1FLT4KDRMAPTKMT2A
SCHEMBL5032634 0.87 FLT1 (0.39) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5034998 0.87 CYP3A4 (0.36) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5032510 0.87 CYP3A4 (0.39) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5032532 0.85 NPC1 (0.37) FLT1FLT4KDRTSHRCYP3A4
SCHEMBL5036081 0.85 CYP3A4 (0.35) FLT1FLT4KDRTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 FLT1 1346/4885FLT4 1463/4885KDR 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.